Anders Gaarsdal Holst

Anders Gaarsdal Holst has a long and varied work history, starting in 1999 as an IT consultant for web-based solutions for clinical research. In 2006, they began working as a medical doctor in Copenhagen, followed by a medical doctor position in a Norwegian medical practice in 2007. In 2008, they began working as a medical doctor and research fellow at Rigshospitalet, Department of Cardiology, where they completed a PhD in the field of cardiovascular genetics and epidemiology. Anders Gaarsdal also founded and chaired the Copenhagen ECG Study, a cohort study of nearly 400. In 2013, they began working as a medical doctor at Bispebjerg Hospital, Department of Cardiology, while also taking on a Senior International Medical Manager role at Novo Nordisk. In this role, they specialized in cardiovascular aspects of clinical development within diabetes, and was medical manager on SUSTAIN 6, the semaglutide cardiovascular outcome trial. Anders Gaarsdal was also lead medical director for cardiovascular outcome trials, and lead senior medical director on cardiovascular clinical development activities across the company portfolio. In 2020, they became Chief Executive Officer and Chief Medical Officer at Acesion Pharma.

Anders Gaarsdal Holst completed a PhD in Medical Genetics and Epidemiology from Københavns Universitet - University of Copenhagen between 2008 and 2011. Anders Gaarsdal also completed a cand.med. in Medicine from Københavns Universitet - University of Copenhagen between 1998 and 2005. During 2003 and 2004, they completed a cand.med. in Medicine from Humboldt-Universität zu Berlin.